ImmunityBio Seeks Expanded FDA Approval for Key Cancer Drug

ImmunityBio is advancing the commercial potential of its flagship therapy, ANKTIVA, with a new regulatory submission to the U.S. Food and Drug Administration (FDA). The biotech firm has officially filed to extend the drug’s approval to cover an additional group of bladder cancer patients. This move is bolstered by updated medical guidelines and growing confidence from financial analysts.

The supplemental application seeks authorization to use ANKTIVA in combination with the standard BCG therapy for individuals diagnosed with specific papillary tumors. This strategy is supported by revised National Comprehensive Cancer Network (NCCN) guidelines, which now formally include this combination treatment. Long-term data from the QUILT-3.032 clinical trial, demonstrating durable response rates in participants, underpin the efficacy case for this expanded use.

Financial Backing and Analyst Upgrades

The drug’s accelerating commercial trajectory is drawing increased attention from institutional investors. Following a surge in U.S. net sales to approximately $113 million in 2025—a gain of roughly 700 percent—market researchers now project revenue could reach as high as $195 million in 2026. This fundamental progress is reflected in recent analyst actions:

• BTIG: Initiated coverage with a “Buy” rating and a $13.00 price target.
• Piper Sandler: Raised its price target from $7.00 to $12.00.
• Consensus Estimate: The average price target among analysts stands at $14.80.

Compared to yesterday’s closing share price of $8.47, these assessments indicate significant upside potential for the company, which carries a market valuation of $8.7 billion.

Should investors sell immediately? Or is it worth buying ImmunityBio?

Global Regulatory Momentum and Pipeline Updates

Alongside its U.S. efforts, ImmunityBio is making strides in international markets. The pharmaceutical authority in Macau granted approval for ANKTIVA, building on prior authorizations from the FDA and the European Medicines Agency (EMA). The company has previously secured conditional marketing approval in the European Union and received clearance to treat lung cancer in Saudi Arabia.

Progress extends beyond the lead product. The clinical programs for its NK cell therapy demonstrated a favorable safety profile across 74 trial participants. Furthermore, the company achieved a critical manufacturing milestone, with its platform now successfully processing material from more than 60 different donors. This advancement helps ensure the future scalability of its cell therapies.

With cash reserves recently reported at nearly $243 million, ImmunityBio appears financially prepared for upcoming regulatory and commercial initiatives. The pending FDA decision on expanding ANKTIVA’s label now represents the next major catalyst for the company’s operational development.